论文部分内容阅读
[目的]探讨益赛普联合柳氮磺吡啶治疗类风湿性关节炎的临床疗效。[方法]按照随机数字法将80例类风湿性关节炎患者随机分为观察组和对照组,其中观察采用益赛普联合柳氮磺吡啶治疗,并与单独给予柳氮磺吡啶治疗的对照组进行了临床疗效对比。[结果]观察组治疗后的晨僵、关节压痛指数、关节肿胀指数、关节肿胀数、关节压痛数等临床指标均明显低于对照组治疗后的水平(P﹤0.05)。观察组的ESR、CRP、IgG、IgA、IgM等实验室指标均明显低于治疗前,且ESR、CRP、IgG、IgA等亦明显低于对照组治疗后的水平,差异具有统计学意义(P﹤0.05)。观察组的总有效率明显高于对照组P﹤0.05)。两组不良反应发生率无明显差异(P﹥0.05)。[结论]益赛普联合柳氮磺胺吡啶治疗较单用柳氮磺胺吡啶可以更快减轻早期RA症状,延缓关节破坏,疗效肯定。
[Objective] To investigate the clinical efficacy of Yi Sip combined with sulfasalazine in the treatment of rheumatoid arthritis. [Method] According to the random number method, 80 patients with rheumatoid arthritis were randomly divided into observation group and control group. The observation was treated with Yisuipu combined with sulfasalazine and the control group treated with sulfasalazine alone The clinical efficacy comparison. [Results] The morning stiffness, joint tenderness index, joint swelling index, joint swelling index and joint tenderness index of the observation group were significantly lower than those of the control group after treatment (P <0.05). The ESR, CRP, IgG, IgA, IgM and other laboratory indexes of the observation group were significantly lower than those before treatment, and the levels of ESR, CRP, IgG and IgA in the observation group were also significantly lower than those in the control group, the difference was statistically significant (P <0.05). The total effective rate of the observation group was significantly higher than that of the control group (P <0.05). No significant difference in the incidence of adverse reactions between the two groups (P> 0.05). [Conclusion] The combination of Yipipu and sulfasalazine is more effective than sulfasalazine alone in reducing early RA symptoms and delaying joint destruction.